Summitt syndrome

Summitt syndrome (also known as craniosynostosis-obesity-hypogenitalism-mental retardation syndrome or Summitt acrocephalosyndactyly) is an extremely rare genetic disorder characterized by the combination of craniosynostosis (premature fusion of skull sutures), syndactyly (fusion of fingers and/or toes), obesity, and intellectual disability. The condition was first described by Summitt in 1969 and belongs to the broader group of acrocephalosyndactyly syndromes. The syndrome primarily affects the skeletal system, particularly the skull and extremities, as well as the central nervous system and endocrine/metabolic systems. Key clinical features include turribrachycephaly (a tall, short skull shape resulting from craniosynostosis), cutaneous syndactyly of the hands and feet (particularly involving the third and fourth fingers), gynecomastia, obesity, and varying degrees of cognitive impairment. Some patients may also exhibit hypogenitalism and other craniofacial anomalies. The ICD-10 classification places this condition under hereditary lymphedema (Q82.0), though its primary manifestations are skeletal and neurodevelopmental. Treatment for Summitt syndrome is symptomatic and supportive. Surgical intervention may be required for craniosynostosis to prevent increased intracranial pressure and to improve skull shape, as well as for correction of syndactyly to improve hand function. Management of obesity and endocrine abnormalities, along with educational support for intellectual disability, form important components of the multidisciplinary care approach. Due to the extreme rarity of this condition, no specific targeted therapies exist, and long-term prognosis data are limited.

Common questions about Summitt syndrome